Medtronic, Inc. (Minneapolis, MN, U.S.), a maker of medical devices, announced the launch of its Resting Heart(TM) System for cardiopulmonary bypass.
Employing Medtronic's new Active Air Removal technology, the Resting Heart System is said to be designed to address many of the clinical issues traditionally associated with procedures requiring a heart-lung machine. These include early and midterm mortality, neurocognitive dysfunction, and stroke.
Approximately 75 percent of the 350,000 coronary bypass grafting operations that take place in the U.S. each year are performed on a stopped heart utilizing a heart-lung machine to support the patient while the heart is stopped.
When using the Resting Heart System, the patient's blood is less diluted, and exposure to air and other foreign surfaces is minimized, Medtronic claims. According to the company, recent studies have suggested that employing strategies for fluid management using cardiopulmonary circuits with low-priming volumes results in fewer post-surgical complications, resulting in reduced mortality.
Back to Breaking News